RXRX is trading 5.7% up now at $3.88, extending a week-long run of steady gains. The move appears driven by continued positive sentiment around its AI-driven drug discovery platform and recent clinical and partnership updates, rather than any single new headline today. Shares have been climbing since late June as investors re-engage with the AI biotech narrative amid generally supportive broader market conditions.